Potential merger could create global leader in treating rare-disease treatments with annual sales worth $20bn

London-listed drug company Shire has made a $30bn (£19.2bn) unsolicited takeover offer for the rare-disease specialist Baxalta.

Shire announced it was ready to pay $45.23 (£28.96) per Baxalta share, a 36% premium on Baxalta’s stock price on Monday. Merging the two companies would create “the global leader in [treating] rare diseases” with combined sales of $20bn by 2020, Shire said.

Continue reading…
Source: The Guardian Circular Economy RSS